HFM
NBIX icon

Harvest Fund Management’s Neurocrine Biosciences NBIX Stock Holding History

Harvest Fund Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,254
Closed -$161K – 775
2024
Q4 		$161K Buy
+1,254
New +$155K 0.01% 482
2023
Q1 		– Sell
-1,096
Closed -$131K – 792
2022
Q4 		$131K Buy
+1,096
New +$128K 0.03% 280
2021
Q2 		– Sell
-135
Closed -$13K – 814
2021
Q1 		$13K Buy
+135
New +$14.2K ﹤0.01% 729
2018
Q4 		– Sell
-1,756
Closed -$216K – 407
2018
Q3 		$216K Buy
1,756
+1,336
+318% +$152K 0.04% 151
2018
Q2 		$41K Buy
+420
New +$37.6K 0.01% 222

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Harvest Fund Management's NBIX Position: Q1 2025 in Review

Harvest Fund Management sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 1,254 shares — an estimated $161K sold.

Harvest Fund Management first reported a position in NBIX in Q2 2018 and held it in 5 quarters. The position peaked at $216K in Q3 2018. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Harvest Fund Management reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Harvest Fund Management sold 1,254 Neurocrine Biosciences shares in Q1 2025, an estimated $161K.
  • Harvest Fund Management first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 5 quarters.
  • Harvest Fund Management's Neurocrine Biosciences position peaked at $216K in Q3 2018.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Harvest Fund Management's 13F filing for Q1 2025, filed 8 May 2025.